Grant ID

98-RC-305-4

Illness

Bipolar Disorder

Primary Drug/Intervention

Oxcarbazepine

Primary Dosage

900-1200mg

Secondary Drug Intervention

N/A

Secondary Dosage

N/A

Other Drug/Intervention

N/A

Other Dosage

N/A

Status

Completed

Investigator

Walden

Sample Size

0

Duration of Study Period for Each Subject

5 weeks

Outcome Measurements

YMRS

Results

Patients with acute mania received oxcarbazepine for 14 days, no drug for 7 days, and oxcarbazepine again for 14 days. Four of 12 patients experienced a 50% reduction in YMRS scores. Six patients withdrew prematurely from the trial due to side effects or lack of efficacy.

Publication

Hummel B, Walden J, Stampfer R, Dittmann S, Amann B, Sterr A, Schaefer M, Frye MA, Grunze H. Acute antimanic efficacy and safety of oxcarbazepine in an open trial with an on-off-on design. Bipolar Disorder 2002;4:412-417.

Link

http://www.ncbi.nlm.nih.gov/pubmed/12519102

PI Name

Joerg Walden

Degree

MD

Center

University of Frieburg

Institution

N/A

Address

City or Town

Freiburg

State or Province

N/A

Zip or Postal Code

N/A

Country

Germany

Email Address

JOERG_WALDEN@psyallg.ukl.uni-freiburg.de